RxDoctor Payments Data

Matthew Neil, MD

Family Medicine · Eldridge, IANPI 1578569091

Payments from drug & device makers

$415in general payments, 2019–2025

Across 24 payments — averaging $17.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$158
  • AbbVie$83
  • Pfizer$40
  • Johnson & Johnson$29
  • Esperion Therapeutics, Inc.$21
  • AstraZeneca$19
  • plus $66 from 4 others

What the payments were for

  • Food & beverage$415100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$415 in reported general payments places this provider in the 70th percentile of 1,357 family medicine providers in Iowa.

See all family medicine providers in Iowa

Medicare billing

Part B allowed, 2024
$178,243
Medicare patients
347
Services billed
1,960

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide65$74,796
EliquisApixaban67$71,009
JanuviaSitagliptin Phosphate34$34,509
XareltoRivaroxaban41$30,070
Trelegy ElliptaFluticasone/Umeclidin/Vilanter23$26,238
JardianceEmpagliflozin20$21,114
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog36$19,550
FarxigaDapagliflozin Propanediol12$16,554
MyrbetriqMirabegron11$14,086
Arnuity ElliptaFluticasone Furoate27$10,624
Xtampza ErOxycodone Myristate11$10,549
Spiriva RespimatTiotropium Bromide13$8,395
Lantus SolostarInsulin Glargine,hum.Rec.Anlog48$8,317
Combivent RespimatIpratropium/Albuterol Sulfate12$5,923
Breo ElliptaFluticasone/Vilanterol13$5,152

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Novolog$158$77,85878 claims
PfizerEliquis$40$71,00967 claims
Boehringer IngelheimJardiance, Spiriva Respimat, Combivent Respimat$19$35,43145 claims
Johnson & JohnsonXarelto$29$30,07041 claims
AstraZenecaFarxiga$19$16,55412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,357 family medicine providers in Iowa.

Other family medicine in Eldridge

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →